Biogen's Aduhelm records one patient death. Is the controversial Alzheimer’s drug to blame?

Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use.

One patient death after treatment with Aduhelm was reported to the FDA Adverse Event Reporting System (FAERS), according to the agency’s latest update rounding up cases it had received through the end of September. The fatal case came from a 75-year-old female in Canada after she was diagnosed with brain swelling and bleeding, or amyloid-related imaging abnormality (ARIA).